Pages that link to "Q33886261"
Jump to navigation
Jump to search
The following pages link to Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis (Q33886261):
Displaying 50 items.
- Immunotherapy for metastatic renal cell carcinoma (Q24186688) (← links)
- Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines (Q26772715) (← links)
- Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities (Q26852437) (← links)
- Cancer immunotherapy via dendritic cells (Q29615444) (← links)
- Immunotherapy for metastatic renal cell carcinoma (Q30234458) (← links)
- CD40-activated B cells induce anti-tumor immunity in vivo (Q33709425) (← links)
- Clinical use of dendritic cells for cancer therapy. (Q34421850) (← links)
- Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines (Q34477358) (← links)
- Optimizing dendritic cell-based approaches for cancer immunotherapy (Q34637535) (← links)
- Anti-CD27 Antibody Potentiates Antitumor Effect of Dendritic Cell-Based Vaccine in Prostate Cancer-Bearing Mice (Q34993204) (← links)
- Monocytes loaded with indocyanine green as active homing contrast agents permit optical differentiation of infectious and non-infectious inflammation (Q35055316) (← links)
- Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment (Q35063621) (← links)
- Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvant (Q35125382) (← links)
- Proposed mechanisms of action for prostate cancer vaccines. (Q35174754) (← links)
- Widespread Non-Canonical Epigenetic Modifications in MMTV-NeuT Breast Cancer (Q35555414) (← links)
- Giardia duodenalis: dendritic cell defects in IL-6 deficient mice contribute to susceptibility to intestinal infection (Q35788532) (← links)
- Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma (Q35799377) (← links)
- Addition of CpG ODN and Poly (I:C) to a standard maturation cocktail generates monocyte-derived dendritic cells and induces a potent Th1 polarization with migratory capacity (Q35887255) (← links)
- Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma. (Q35887319) (← links)
- A STATus report on DC development (Q36188887) (← links)
- The FDA guidance on therapeutic cancer vaccines: the need for revision to include preventive cancer vaccines or for a new guidance dedicated to them (Q36248790) (← links)
- Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma (Q36710917) (← links)
- Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer (Q36820371) (← links)
- IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity (Q37052943) (← links)
- Dendritic cell targeted vaccines: Recent progresses and challenges (Q37135259) (← links)
- Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study (Q37514725) (← links)
- Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis (Q37578705) (← links)
- Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine (Q37971324) (← links)
- Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm? (Q38008023) (← links)
- Cell-based drug-delivery platforms (Q38029631) (← links)
- Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review (Q38059513) (← links)
- Dendritic cell-based vaccination for renal cell carcinoma: challenges in clinical trials (Q38059516) (← links)
- Dendritic cell subsets in mycobacterial infection: control of bacterial growth and T cell responses (Q38061211) (← links)
- Dendritic cell immunotherapy in ovarian cancer (Q38069183) (← links)
- Tracking and evaluation of dendritic cell migration by cellular magnetic resonance imaging (Q38103222) (← links)
- Current status and future perspectives of dendritic cell-based cancer immunotherapy. (Q38106733) (← links)
- CD40-activated B cells as antigen-presenting cells: the final sprint toward clinical application (Q38113268) (← links)
- Oncolytic vaccines (Q38152474) (← links)
- A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma (Q38172644) (← links)
- Various ways to improve whole cancer cell vaccines (Q38206582) (← links)
- Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use? (Q38212485) (← links)
- mRNA-based dendritic cell vaccines. (Q38246769) (← links)
- Overcoming tumor-mediated immunosuppression (Q38262255) (← links)
- Dendritic cell-based vaccine research against cancer. (Q38281782) (← links)
- Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. (Q38571694) (← links)
- Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T). (Q38720221) (← links)
- Understanding dendritic cell immunotherapy in ovarian cancer (Q38808249) (← links)
- PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. (Q39143622) (← links)
- Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy (Q39234940) (← links)
- Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model (Q39301153) (← links)